Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration's September 1, 2021, data safety communication - 09/12/21
Doi : 10.1016/j.jaad.2021.09.051
Morgan Murphrey, MD a, Reid Alexander Waldman, MD b, ⁎ 
, Timothy Durso, MD c, Jane M. Grant-Kels, MD d
, Timothy Durso, MD c, Jane M. Grant-Kels, MD d a Department of Dermatology, University of California, Davis, California
b Dermatology Associates of Glastonbury, Glastonbury, Connecticut
c Department of Dermatology at Joint Base Andrews, Joint Base Andrews, Maryland
d Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut
∗Correspondence and reprint requests to: Reid Alexander Waldman, MD, Dermatology Associates of Glastonbury, 21 South Road, Glastonbury, CT 06132.Dermatology Associates of Glastonbury21 South RoadGlastonburyCT06132
Key words : abrocitinib, alopecia areata, atopic dermatitis, baricitinib, Janus kinase inhibitor, psoriasis, ruxolitinib, tofacitinib, upadacitinib
Abbreviations used : FDA, JAKi
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| IRB approval status: Not applicable. |
© 2021
American Academy of Dermatology, Inc. Tous droits réservés.
Vol 86 - N° 1
P. 42-43 - janvier 2022 Retour au numéro
Article précédent
- This month in JAAD International: February 2022: Vitiligo in melanoma patients treated with antiprogrammed cell death-1 therapies and improved survival
- Jonathan Kantor
- Retinoids in ichthyosis and disorders of cornification: Tipping the scales toward optimal use
- Warren R. Heymann
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?